EUVIMEDEUVIMED entdecken
Crossref

Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity

Angelo Oneto iD, Ghazl Al Hamwi, Laura Schäkel, Nadine Krüger, Katharina Sylvester, Marvin Petry, Rasha Abu Shamleh, Thanigaimalai Pillaiyar iD, Tobias Claff iD, Anke C Schiedel, Norbert Sträter iD, Michael Gütschow iD und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Angelo Oneto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Coronavirus 3C Proteases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Volkswagen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 infections pose a high risk for vulnerable patients. In this study, we designed benzoic acid halopyridyl esters bearing a variety of substituents as irreversible inhibitors of the main viral protease (Mpro). Altogether, 55 benzoyl chloro/bromo-pyridyl esters were synthesized, with broad variation of the substitution pattern on the benzoyl moiety. A workflow was employed for multiparametric optimization, including Mpro inhibition assays of SARS-CoV-2 and related pathogenic coronaviruses, the duration of enzyme inhibition, the compounds' stability versus glutathione, cytotoxicity, and antiviral activity. Several compounds showed IC50 values in the low nanomolar range, kinact/Ki values of >100,000 M-1 s-1 and high antiviral activity. High-resolution X-ray cocrystal structures indicated an important role of ortho-fluorobenzoyl substitution, forming a water network that stabilizes the inhibitor-bound enzyme. The most potent antiviral compound was the p-ethoxy-o-fluorobenzoyl chloropyridyl ester (PSB-21110, 29b, MW 296 g/mol; EC50 2.68 nM), which may serve as a lead structure for broad-spectrum anticoronaviral therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2Coronavirus 3C ProteasesHumansStructure-Activity RelationshipProtease InhibitorsCrystallography, X-RayChlorocebus aethiopsAnimalsVero CellsDrug Design

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn D-53121, Germany.
  • PharmaCenter Bonn, University of Bonn, Brühler Straße 7, Bonn D-53121, Germany.
  • Platform Infection Models, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, Göttingen 37077, Germany.
  • Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, Leipzig 04103, Germany.

ORCID-Profile: Angelo Oneto, Thanigaimalai Pillaiyar, Tobias Claff, Norbert Sträter, Michael Gütschow, Christa E Müller

Förderung

  • Volkswagen Foundation

Zitieren

APA

Oneto, A., Hamwi, G. A., Schäkel, L., Krüger, N., Sylvester, K., Petry, M., Shamleh, R. A., Pillaiyar, T., Claff, T., Schiedel, A. C., Sträter, N., Gütschow, M., & Müller, C. E. (2024). Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00535

Vancouver

Oneto A, Hamwi GA, Schäkel L, Krüger N, Sylvester K, Petry M, et al. Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00535

BibTeX
@article{Oneto2024,
  author = {Oneto, Angelo and Hamwi, Ghazl Al and Schäkel, Laura and Krüger, Nadine and Sylvester, Katharina and Petry, Marvin and Shamleh, Rasha Abu and Pillaiyar, Thanigaimalai and Claff, Tobias and Schiedel, Anke C and Sträter, Norbert and Gütschow, Michael and Müller, Christa E},
  title = {Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00535}
}
Kostenlos starten →